FDA authorizes Eli Lilly antibody drug that Trump touted, but supply will be limited

Health experts have championed the medicine as a powerful tool to change the course of the pandemic and work as a bridge to a vaccine. But the initial scarcity of the drug and the logistical complexities of administering it could mute its immediate impact on the pandemic.

View original article
Contributor: Carolyn Y. Johnson